losartan and serine

losartan has been researched along with serine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bihoreau, C; Clauser, E; Conchon, S; Corvol, P; Curnow, KM; Monnot, C1
Fujino, M; Imaizumi, S; Kanazawa, T; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K1
Andreozzi, F; Laino, I; Martino, F; Musca, D; Perticone, F; Perticone, M; Presta, I; Sciacqua, A; Sesti, G; Tassone, EJ1

Other Studies

3 other study(ies) available for losartan and serine

ArticleYear
Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants.
    The Journal of biological chemistry, 1996, Jan-19, Volume: 271, Issue:3

    Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Asparagine; Base Sequence; Binding Sites; Biphenyl Compounds; Cell Line; Chlorocebus aethiops; CHO Cells; Cricetinae; DNA Primers; Imidazoles; Inositol Phosphates; Kinetics; Losartan; Molecular Sequence Data; Mutagenesis; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Oligopeptides; Point Mutation; Polymerase Chain Reaction; Rats; Receptors, Angiotensin; Recombinant Proteins; Sequence Deletion; Serine; Tetrazoles; Transfection

1996
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
    Molecular endocrinology (Baltimore, Md.), 2008, Volume: 22, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Chlorocebus aethiops; Computer Simulation; COS Cells; Imidazoles; Losartan; Lysine; Molecular Structure; Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Receptor, Angiotensin, Type 1; Serine; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan

2008
Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs.
    Atherosclerosis, 2011, Volume: 219, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Cells, Cultured; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Losartan; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Serine; Signal Transduction; Tyrosine

2011